Recce Pharmaceuticals Ltd has signed a Cooperative Research and Development Agreement (CRADA) with the US Army Medical Research Institute of Infectious Diseases (USAMRIID), backed by funding from the Defense Threat Reduction Agency (DTRA).
Partnerships with US government
The collaboration with USAMRIID further strengthens Recce’s partnerships with US government agencies to address global threats posed by antimicrobial resistance and biological warfare agents.
“We are thrilled to enter into another US Department of Defense Research program, this time with the United States Army Medical Research Institute of Infectious Diseases and are very thankful for our partners at USAMRIID and DTRA,” CEO James Graham said.
“This program will see the US Army test R327 against some of the world’s deadliest pathogens and comes in addition to an ongoing DoD burn wound program, further bolstering Recce’s on-going US Government partnerships.”
Under the agreement, Recce’s synthetic anti-infective, RECCE® 327 (R327), will be tested against a panel of highly hazardous biodefence pathogens using USAMRIID’s established in vitro infection models under high biocontainment conditions.
Successful testing may lead to progression into small animal model studies.
Combatting biological threats
The CRADA is part of broader ongoing initiatives with the US Department of Defense, complementing a recently awarded US$2 million grant through the Congressionally Directed Medical Research Program (CDMRP) for the evaluation of R327G as a gel-based treatment for burn wound infections.
USAMRIID serves as the United States Army’s premier institution for defensive research against biological threats and is the only facility within the Department of Defense certified for Biosafety Level 4 containment studies.
R327 is a broad-spectrum synthetic anti-infective designed to combat both Gram-positive and Gram-negative bacteria, including drug-resistant strains.
It has demonstrated efficacy without signs of resistance and has shown favourable safety and efficacy profiles across clinical and pre-clinical studies.